Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum TELESTA THERAPEUTICS INC T.TST

"Telesta Therapeutics Inc is a biopharmaceutical company. The Company is engaged in the research, development, manufacturing and commercialization of human health products and technologies."

TSX:TST - Post Discussion

View:
Post by Calicalicali on Apr 13, 2016 9:51am

Asks

4.7 mil to break 0.14 

the shorting % of this stock is Ludacris
Comment by 1wascallywabbit on Apr 13, 2016 10:03am
It's because the shorters believe there will be a negative result from the meeting, either killing it altogether or at least requiring a major trial. The only way to get a significant rally on substance is for the result if the meeting to be really positive. This lift today is just hype and gives the shorters a better price to place their bets at.
Comment by DamnYankees on Apr 13, 2016 10:11am
The pop gun rally is over. Now reality ( or Telesta's version of reality) will settle back in and shareholders will start wondering where the next axe will fall on them. Even marginally good news will be perceived as negative. That is just how the ball rolls here
Comment by Tson99 on Apr 13, 2016 10:53am
The type A meeting will be just what the other poster said a meeting to determine a pathway going forward for MCNA. The result will most likely be that they will be required to run another phase 3 trial as it was mapped out with Endo years ago. The plan was always to have a second phase 3 trial going directly against BCG. When they partnered with Endo that was the plan until Endo changed the trial ...more  
Comment by ragingbull1234 on Apr 13, 2016 11:04am
If you need to organize a MEETING at this point in time to discuss yet ANOTHER path for this treatment to take, then the brains of everyone involved is worth an aggregate of ZERO.    Can you see people like Stephen Wolfram behaving like this?    The guy went from BIRTH-TO-PHD in a shorter time than the FDA has had to assess Bioniche/Telesta.   When he can attain his PhD by ...more  
Comment by ragingbull1234 on Apr 13, 2016 11:10am
if the people in power aren't terrible at their jobs, then how do you explain the "banking crisis"?    How the hell is it possible for DEFLATION to occur inside of this system?   It occurs because the system sucks by design 
Comment by ragingbull1234 on Apr 13, 2016 11:27am
If MCNA improves the quality of life and increases the chance that a NMIBC patient survives, and it's only worth $31 million Canadian dollars because the FDA is the judge, then dollars aren't worth anything at all.    Wtf good has Blackberry done with billions of dollars?   LOST THEM.   Yet the same dummies get up every day and go to work at Blackberry to collect (again ...more  
Comment by LYNXSECRET on Apr 13, 2016 11:12am
LOL BIONICHE WHAT A JOKE WAS THAT LOL..... WAS RUNNED BY CON ARTISTS..... I KNEW MOST PEOPLE THAT WORKED THERE LOL .... I BET ITS THE SAME POOP DIFFERENT SMELL... THEY SAY THEY THEY KNOW STUFF AND PUSH POOP AND SEE IF IT STICKS LOL
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities